Joint Clinical Assessment, JCA
Cosibelimab (cutaneous squamous cell carcinoma)
Dossier assessment
Indication:
Tretament of cutaneous squamous cell carcinoma
Timetable
- 2nd quarter, 2026
- Start
- 2nd quarter, 2026
- voraussichtlicher Abschluss
Project details
- Project no.
- MP-202525
- Report type
- Joint Clinical Assessment, JCA
- Status
- Commission work started
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
his Joint Clinical Assessment (JCA) is being conducted in cooperation with the Haute Autorité de santé (HAS) France.
Further background information can be found here: European health technology assessment